Search
Cisplatin Treatment Options
A collection of 1441 research studies where Cisplatin is the interventional treatment. These studies are located in the United States . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-Small Cell Lung Cancer.
1429 - 1440 of 1441
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC
Completed
This is a Phase II study of paclitaxel (Taxol R) administered as a 96-hour (4 day) continuous infusion followed by a bolus of cisplatin for previously untreated patients with stage III/IV or relapsed non-small cell lung cancer (NSCLC). The goal of this phase II study is to determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in patients with advanced NSCLC.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
Completed
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
Completed
Two days prior to planned surgery, paclitaxel is infused IV over 24 hours.
Patients will undergo cytoreductive surgery, to debulk tumor. Scope of procedure will vary with each patient, including a spectrum of possible procedures, such as splenectomy, liver resection, pancreatic resection or bowel resection.
After cytoreductive surgery, continuous hyperthermic peritoneal perfusion (CHPP) surgery with cisplatin will begin by placing an influx and efflux catheters via abdominal wall. Perfusion ra... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Carcinoma, Peritoneal Neoplasm
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
Terminated
The purpose of this study is to determine the maximum tolerated dose (MTD) of topotecan when given weekly with cisplatin in patients with persistent, recurrent, or advanced stage cervical cancer. Secondary purposes are to describe the toxicity profile in patients with persistent, recurrent, or advanced stage cervical cancer treated with the combination of topotecan when given weekly with cisplatin and to determine the response rate and time to progression in patients with persistent, recurrent,... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
02/13/2008
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cervix Cancer
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Completed
In the United States, the incidence of biliary tract cancer and gallbladder cancer has been estimated to be 6,000-8,000 patients per year. Currently, there is no standard therapy for these tumors once the disease has spread and is inoperable. Recent small studies with gemcitabine have shown a positive response rate. The investigators plan to test the combination of gemcitabine with cisplatin for biliary tract and gallbladder cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2007
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Gallbladder Cancer, Biliary Tract Cancer
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
Completed
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Birmingham, Alabama +18 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Terminated
The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2007
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Head and Neck Cancer
Study of Talabostat and Cisplatin in Advanced Melanoma
Completed
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2007
Locations: University of Arkansas Medical Sciences, Little Rock, Arkansas +12 locations
Conditions: Melanoma, Skin Cancer
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Approved For Marketing
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2007
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Basking Ridge, New Jersey +5 locations
Conditions: Mesothelioma
Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
Completed
To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina
Conditions: Carcinoma, Non Small Cell Lung
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
Completed
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2006
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas
Conditions: Carcinoma, Transitional Cell
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
Completed
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Springdale, Arkansas +7 locations
Conditions: Lung Neoplasms
1429 - 1440 of 1441